Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Genetic Polymorphisms of Pharmacogenomic VIP Variants in the Yi Population from China

Genetic Variability of CYP4F2, CYP2D6, CYP2E1, and ACE in the Chinese Yi Population

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China

Very important pharmacogenetic variants landscape and potential clinical relevance in the Zhuang population from Yunnan province

Identification and Functional Assessment of Eight CYP3A4 Allelic Variants 39-46 Detected in the Chinese Han Population

Differences in Genotype and Allele Frequency Distributions of Polymorphic Drug Metabolizing Enzymes CYP2C19 and CYP2D6 in Mainland Chinese Mongolian, Hui and Han Populations

Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects

[Polymorphisms of Drug-Metabolizing Enzymes Genes in a Han Chinese Population].

The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations

Systematic Screening for Polymorphisms in the CYP3A4 Gene in the Chinese Population.

Genetic Polymorphism Analysis of CYP2C19 in Chinese Han Populations from Different Geographic Areas of Mainland China

Analysis of Cyp3a4 Genetic Polymorphisms in Han Chinese

Candidate Gene and Pathway Analyses Identifying Genetic Variations Associated with Prasugrel Pharmacokinetics and Pharmacodynamics.

Genetic Polymorphisms in Mdr1 and Cyp3a5 and Mdr1 Haplotype in Mainland Chinese Han, Uygur and Kazakh Ethnic Groups

Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy.

Distribution of related single nucleotide polymorphisms of drug transporters in healthy Chinese Han population

Allele and Genotype Frequencies of CYP3A4, CYP3A5, CYP3A7, and GSTP1 Gene Polymorphisms among Mainland Tibetan, Mongolian, Uyghur, and Han Chinese Populations.

Genetic architectures of ADME genes in five Eurasian admixed populations and implications for drug safety and efficacy.

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Functional Allele and Genotype Frequencies of CYP1A2 ,CYP2B6 and Inos among Mainland Chinese Tibetan, Mongolian, Uygur and Han Populations